A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study To Evaluate The Ef?cacy And Safety Of BIIB074 (Vixotrigine) In Subjects With Trigeminal Neuralgia Biogen Pharmaceuticals Aug 4, 2020 Role: Principal Investigator |
Long-Term Efficacy of Neuronavigation-Guided rTMS in Alleviating Headache and Pain In GWI (Multicenter Study) DOD W81XWH1910691Oct 2, 2019 Role: Lead Principal Investigator |
rTMS in alleviating Pain and Co-morbid symptoms in GWVI NIH I01CX001986Oct 1, 2019 - Sep 30, 2024 Role: Lead Principal Investigator |
Long Term efficacy of rTMS in Managing MTBI-related Headache NIH I01RX002506Jan 1, 2018 - Sep 30, 2023 Role: Principal Investigator |
A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 1 Subcutaneous Dose Regimen of Fremanezumab Versus Placebo for the Prevention of Persistent Posttraumatic Headache TEVA Pharmaceutical Jan 30, 2017 Role: Principal Investigator |
Improving functions in Veterans with Post-Traumatic Peripheral Neuropathic Pain NIH I21RX002366Oct 1, 2016 - Sep 30, 2019 Role: Principal Investigator |
Alleviating headache and pain in GWI with Neuronagvigation-Guided rTMS DOD W81XWH-16-1-0754Oct 1, 2016 - Sep 30, 2019 Role: Principal Investigator |
Improving Functions in MTBI Patients with Headache by rTMS NIH I21RX001359Jan 1, 2014 - Sep 30, 2016 Role: Principal Investigator |
A randomized double-blind placebo controlled parallel group study of the efficacy and safety of pregabalin in subjects with post-traumatic peripheral neuropathic pain Pfizer Pharmaceutical Feb 1, 2012 Role: Principal Investigator |
Sanofi-Aventis: Randomized, double blind, placebo-controlled study of the effect of a single injection of SAR164877 (REGN475) on reduction of pain in patients with pancreatitis Sanofi-Aventis May 4, 2010 Role: Principal Investigator |
Sanofi Aventis: Randomized, double blind, placebo-controlled study of the effect of a single injection of SAR164877 (REGN475) on reduction of pain from vertebral fracture associated with osteoporosis Sanofi Aventis Mar 1, 2010 Role: Principal Investigator |
Archimedes: CP043/06/FCNS: A Multicenter, Placebo-Controlled, Double-Blind, Two Phase Crossover Study of Nasalfent (Fentanyl Citrate Nasal Spray) in the Treatment of Breakthrough Cancer Pain (BTCP) in Subjects Taking Regular Opioid Therapy Archimedes Jul 2, 2007 Role: Principal Investigator |
Archimedes: CP045/06/FCNS: An Open-Label Study Investigating Long-term Safety and Tolerability of Nasalfent (Fentanyl Citrate Nasal Spray) in the Treatment of Breakthrough Cancer Pain (BTCP) in Subjects Taking Regular Opioid Therapy Archimedes May 1, 2007 Role: Principal Investigator |
ANS: A Clinical Evaluation of the Eon 16-Channel Implantable Pulse Generator (IPG) in combination with two Octrode leads for the management of back pain and neuropathic leg pain ANS Jun 1, 2006 Role: Principal Investigator |
To study the neuronal mechanism of acupunture analgesia NIH K08AT001695Sep 1, 2003 - Aug 31, 2007 Role: Principal Investigator |